Novartis said on Thursday it has launched a tender offer to acquire MorphoSys , a German developer of cancer treatments, for an aggregate 2.7 billion euros ($2.9 billion). The Swiss drugmaker said its cash offer price of 68 euros per MorphoSys share corresponds to a premium of 142% on the volume-weighted average price during the last three months. Source: Reuters 12/4/2024